Dermira to Present at the 8th Annual SVB Leerink Global Healthcare Conference
21 févr. 2019 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Report Fourth Quarter 2018 Results and Host Conference Call on Tuesday, February 26, 2019
19 févr. 2019 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Almirall and Dermira Enter into Option and License Agreement for European Rights to Lebrikizumab
12 févr. 2019 02h00 HE
|
Dermira, Inc.
- Almirall acquires option to license rights to develop and commercialize lebrikizumab for atopic dermatitis in Europe- Dermira to receive an option fee of $30 million- Lebrikizumab is an...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
11 déc. 2018 17h07 HE
|
Dermira, Inc.
MENLO PARK, Calif., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Enters into Credit Facility with Athyrium Capital Management
04 déc. 2018 07h30 HE
|
Dermira, Inc.
MENLO PARK, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira to Present at Evercore ISI HealthCONx Conference
19 nov. 2018 08h00 HE
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 19, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08 nov. 2018 16h05 HE
|
Dermira, Inc.
MENLO PARK, Calif., Nov. 08, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Reports Third Quarter 2018 Financial Results
07 nov. 2018 16h01 HE
|
Dermira, Inc.
Conference call today at 1:30 p.m. PT / 4:30 p.m. ET MENLO PARK, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing...
Dermira to Report Third Quarter 2018 Results and Host Conference Call on Wednesday, November 7, 2018
31 oct. 2018 16h01 HE
|
Dermira, Inc.
MENLO PARK, Calif., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering...
Dermira Completes Patient Enrollment in Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
23 oct. 2018 16h01 HE
|
Dermira, Inc.
Topline efficacy and safety results anticipated by early April 2019 MENLO PARK, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ: DERM), a biopharmaceutical company...